Top

Advanced Prebreathe and Thermal Monitoring Studies

Active

Federal

Response Deadline08/24/2026, 06:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

National Aeronautics And Space Administration → NASA Johnson Space CenterView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Houston, TX, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedJul 15

subcontract

Response DeadlineAug 24

Submission deadline

Response Deadline

08/24/2026, 06:00:00 PM UTCin about 1 month

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyNational Aeronautics And Space Administration → NASA Johnson Space Center

ContactsNo contacts available

OfficeN/A

Organization / Agency

National Aeronautics And Space Administration → NASA Johnson Space Center

View Agency Profile

Office AddressN/A

ContactsNo contact information available

Full Description

Conduct optional studies on pharmaceutical-enhanced prebreathe, elevated metabolic rates, and core body temperature monitoring to evaluate DCS countermeasures under inflight-like conditions.

Similar Contracts

Same NAICS industry code

NAICS: 541714

New

Federal

Illumina Reagent Kits

Naval Medical Research Center

POSTED

DEADLINE

Battlefield Pain Management – AnalgesicThis solicitation under the Prototype Other Transaction Authority (10 U.S.C. § 4022) seeks innovative analgesic solutions for battlefield use, with the goal of achieving FDA approval for a single-use product intended to manage acute moderate to severe pain in combat settings. The product must be rapid to administer, compact in size and weight for individual carrying, and capable of functioning without refrigeration across extreme temperatures ranging from -25°C to 45°C while maintaining a 2-3 year shelf life at controlled room temperature. It must comply with USP <659> and MIL-STD-810 environmental standards, adhere to 21 CFR Part 820 quality system requirements for labeling and packaging, and meet strict physiological limits including no more than a 20% reduction in blood pressure, heart rate, or clotting ability, with only minor, non-ventilation-required airway changes. The product must be classified as a DEA Schedule II or higher controlled substance and may be delivered via nasal spray or autoinjector. The effort spans eight years, divided into three phases: three years for Chemistry Manufacturing Controls and stability studies, two years for non-clinical enabling studies, and three years for clinical trials and human factors testing culminating in potential EUA submission. The contract is structured as an Other Transaction Agreement exempt from FAR and DFARS, except where explicitly referenced, and is not subject to Bayh-Dole provisions. Proposals must demonstrate at least one of three pass/fail conditions: inclusion of a significant nontraditional defense contractor or nonprofit research institution, all non-federal participants being small businesses or nontraditional contractors, or at least one-third of project costs being privately funded. Evaluation focuses on technical approach, management strategy, and cost, with no assigned weights provided. Submission requires three clearly organized volumes in searchable PDF format, accompanied by a Microsoft Project plan, with strict formatting rules prohibiting embellishments. All participants must be registered in SAM with an active UEI and CAGE code, and must include NAICS code 541714. Compliance with prohibitions on malign foreign talent programs is mandatory, requiring certification and disclosure of foreign affiliations, ownerships, and funding sources. Payment occurs through WAWF using NPI, cost vouchers, or invoices tied to CLINs and ACRNs, with acceptance managed by an Agreement Officer Representative. Data deliverables, including CMC reports, clinical study outcomes, and regulatory filings, are governed by CDRL and DID attachments

Defense Health Agency

POSTED

DEADLINE

Development of Light-Responsive Artificial Cells using Plant-Based Photoreceptor SystemsThe United States Army Corps of Engineers Engineer Research and Development Center Construction Engineering Research Laboratory is seeking to develop light-responsive artificial cells by integrating plant-derived UVR8 photoreceptor systems into synthetic biology platforms, using high-throughput protein engineering and AI-assisted structural refinement to create programmable, pseudo-living systems activated by environmental light stimuli. The project aims to advance foundational science in synthetic biology by leveraging Bioconscientia, LLC’s uniquely specialized expertise in UVR8 photoreceptor technology, which enables precise sensing of UV-B light in a manner unmatched by other entities. Due to the highly specialized nature of the required research and Bioconscientia’s irreplaceable knowledge of existing experimental data and technical pathways, the government intends to award a sole-source contract to this vendor under RFO FAR 12.102(a), with an anticipated award date of September 30, 2026. This presolicitation notice, issued under FAR Part 5.101(a) with solicitation number W9132T26QA015 and NAICS code 541714, does not constitute a formal request for proposals or a competitive procurement, nor is it a set-aside. Interested parties may submit capability statements to CERL-CT-QUOTES@USACE.ARMY.MIL by July 31, 2026, to be reviewed for potential technical equivalency, but submission does not guarantee a change to the government’s acquisition strategy. The government retains full discretion to proceed with sole-source award regardless of responses received. All work will be performed in Champaign, Illinois, and the primary point of contact for submissions is Lurline L. Simmons, with Andrea J. Thomas serving as the contracting officer. No telephone inquiries will be accepted.

W2R2 Construction Engrg Labor

POSTED

DEADLINE

AI/ML and Data Analytics for Cardiovascular Device Validation

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is soliciting collaborative participation through a continuous, open Participant Basic Agreement (PBA) under the HEALER portfolio to advance next-generation, threat-agnostic host-directed therapeutics designed to enhance physiological resilience against CBRN threats. This initiative targets five critical biological systems—neurological protection, respiratory stabilization, immune modulation, hematologic and vascular function, and cellular stress and repair pathways—with the goal of developing dual-use medical countermeasures that serve both military and civilian critical care needs. The program invites two categories of collaborators: therapeutic developers with candidates that modulate host response mechanisms and drug development support providers including CROs and CDMOs with capabilities in preclinical testing, clinical trial execution, cGMP manufacturing, regulatory strategy, and advanced modeling. Submission requires a white paper of no more than five pages excluding a cover page, detailing product mechanism of action, efficacy data from validated animal models, regulatory status such as IND experience and clinical trial history, manufacturing capacity and scale-up plans, and company profile for therapeutic developers, or core capabilities and infrastructure for service providers. All participants must express willingness to collaborate with other PBA holders to foster an integrated development ecosystem. The solicitation, issued under statutory authority of 10 U.S.C. §§4021–4023, operates outside the Competition in Contracting Act and does not follow traditional procurement or evaluation frameworks, eliminating standard contract clauses, formal evaluation factors, pricing structures, or submission deadlines. Instead, awards are made at the government’s discretion through a non-traditional acquisition mechanism designed to accelerate innovation. Technical and administrative inquiries are directed to Hunter Robinson and Alexander Mayatte at the U.S. Army’s Aberdeen Proving Ground, Maryland office. Participation prerequisites include current registration in the System for Award Management (SAM), compliance with FDA regulatory pathways, and adherence to cGMP standards for manufacturing. While no specific delivery dates, FOB terms, inspection criteria, or cost estimates are defined, performance is expected to align with the mission of CPE CBRND to enable the Joint Force to operate effectively in CBRN-contested environments. Intellectual property considerations, teaming arrangements, and the scalability of therapeutic candidates are central to selection, with no socioeconomic or size status certifications required. The structure prioritizes agility, collaboration, and cross-sector innovation over rigid compliance, enabling a dynamic pipeline of medical countermeasures capable of addressing evolving biological threats through sustained host resilience.

POSTED

DEADLINE

Non-Optical Methods for High Speed Protein ControlDARPA’s Biological Technologies Office is seeking innovative solutions through the ERIS Marketplace to develop a new class of rapidly switchable, non-optogenetic protein domains capable of enabling real-time, massless control of cellular processes. The goal is to create a robust, modular molecular tool that responds to non-optical external signals such as magnetic fields or focused ultrasound, allowing precise regulation of protein function across cell membranes without relying on light or chemicals. Proposed solutions must achieve activation and deactivation kinetics of no more than two seconds, demonstrate reliable performance through at least 300 repetitive cycles in living cells, and function effectively in both split-protein dimerization and allosteric conformational configurations. This effort explicitly excludes any modifications or enhancements to existing optogenetic, light-based, or chemical systems. The anticipated contract value is $400,000 for a 12-month performance period, with awards being made on a rolling basis as solutions are evaluated, and the government reserves the right to issue awards before the December 8, 2026 submission deadline. Proposals must be submitted via the DARPA Connect ERIS Portal as a video that follows the required title format, or existing awardable solutions may be flagged for consideration by emailing ERIS@darpa.mil with specific subject and body requirements. Evaluation will focus on four core areas: a deep understanding of the problem space and current limitations in fields like sonogenetics and magnetogenetics, a significant technical leap in achieving rapid and repeatable protein control, demonstrated expertise in synthetic biology, protein engineering, and biophysics with a proven track record of quantitative in vivo characterization, and the potential of the solution to become a foundational tool in synthetic biology with broad applications in defense-relevant areas such as biomanufacturing, cell-based therapeutics, and biosensing. All submissions are subject to the ERIS assessment process, which serves as a mandatory pass/fail gate—only solutions deemed awardable by this process will be considered for BTO award. The procuring agency is the Department of Defense through DARPA’s Arlington, VA office, and all participants must comply with the ERIS Master Solicitation requirements available via SAM.gov.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Notice of Intent to Sole Source – University of Maryland Medical Center

National Institutes Of Health - Cc

POSTED

DEADLINE

Limited Competition: Clinical and Translational Science Awards (CTSA) Program: Collaborative and Innovative Acceleration AwardThe Congressionally mandated Clinical and Translational Science Awards (CTSA) Program aims to accelerate the translation of scientific discoveries into practical treatments, diagnostics, and health interventions that enhance patient and public health by funding a national network of academic medical centers. This network provides essential infrastructure, expertise, training, and collaborative platforms needed to move research from the laboratory into clinical practice and community health settings. The current opportunity is a forecast for a limited competition soliciting applications for the Collaborative and Innovative Acceleration Award, designed to support the development and implementation of novel approaches, technologies, or models that amplify the impact of translational research and expedite the delivery of effective therapies to all populations. Funding is authorized under Sections 301 and 405 of the Public Health Service Act, and governed by Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. Eligible organizations may apply under this limited competition, and proposals will undergo standard National Institutes of Health peer review, with funding awarded only to meritorious applications. The announcement is issued by the National Institutes of Health, under the Department of Health and Human Services, with specific inquiries directed to the Division of Clinical Innovation at NCATS. The forecast was posted on July 20, 2026, and further details can be accessed through the official grants.gov listing, though no set-aside type, NAICS code, or specific place of performance is indicated.

National Institutes Of Health

POSTED

DEADLINE

On-Site Technical Deployment and Integration

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Hypoxia Chamber ServicesNASA Johnson Space Center is soliciting offers for Hypoxia Chamber Services under solicitation number 80JSC026Q0008 to support research on the physiological, cognitive, and clinical effects of mild hypobaric hypoxia as part of the Artemis Program. The contract requires comprehensive services including infrastructure, personnel, training, materials, food, supplies, and operational support necessary to conduct controlled hypoxia experiments. This is a combined synopsis and solicitation issued under FAR Subpart 12.6, with no written solicitation to follow, and all information is contained within the posted notice and attachments, particularly Attachment A for the Performance Work Statement and Attachment D for additional submission requirements. The NAICS code is 541714 with a size standard of 1,000 employees, and offerors must self-certify their size status. Evaluation will prioritize Technical Acceptability and Past Performance as significantly more important than Price, though Price becomes increasingly relevant when proposals are closely matched in technical merit. All submissions must include completed representations and certifications per FAR 52.212-3 and comply fully with FAR 52.212-1 and 52.212-4. Proposals must be submitted electronically via email to the designated NASA contacts no later than 1:00 PM CST on August 24, 2026, with questions due by July 29, 2026. The Government assumes no responsibility for electronic submission failures, and late submissions will be rejected per FAR provisions. The place of performance is Houston, Texas, and the Ombudsman clause is applicable for dispute resolution.

NASA Johnson Space Center

POSTED

DEADLINE

Elucidation and Validation of the role of Transporters in the Placenta, Lactating Mammary Gland, Developing Gut, and Blood Brain BarrierThe Eunice Kennedy Shriver National Institute of Child Health and Human Development is advancing its mission to improve maternal, fetal, and child health by launching a second phase of the Transporter Elucidation Network, focused on understanding how biological transporters and local metabolic processes regulate exposure to nutrients, medications, microbiome-derived compounds, and environmental chemicals across critical perinatal barriers. This initiative will develop comprehensive multi-barrier frameworks that connect the maternal gut, placenta, lactating mammary epithelium, infant gut, and infant blood-brain barrier, building on prior organ-specific research to create standardized models, resources, and prototype multi-compartment systems that reflect the dynamic interplay of transporters, their polarity, kinetics, and biotransformation capacities during pregnancy, lactation, and infant development. The goal is to deepen mechanistic insights into how these systems influence nutrient delivery, drug distribution, and neurodevelopmental outcomes in early life. This phase will establish community-wide resources to support integrated studies of perinatal exposure, risk assessment, and targeted interventions across linked maternal-fetal-infant systems, while strengthening collaboration among researchers and accelerating the sharing of tools and data. Emphasis is placed on human-based and developmentally relevant models to ensure biological accuracy and translational impact. The effort also aims to cultivate a next-generation workforce skilled in transporter science, fostering innovation in pediatric pharmacology and neonatal health. Authorized under 42 U.S.C. § 241, the initiative is being led by the Obstetric and Pediatric Pharmacology and Therapeutics Branch of NICHD, with inquiries directed to their designated point of contact, and the opportunity was publicly forecasted on July 16, 2026.

National Institutes Of Health

POSTED

DEADLINE

Hypobaric Chamber Pilot StudiesNASA Johnson Space Center is soliciting offers for pilot chamber testing facilities capable of conducting hypobaric Decompression Sickness (DCS) studies under solicitation number 80JSC026Q0006, issued as a combined synopsis and solicitation per FAR Part 12 for commercial products and services. The requirement calls for three test days of data collection and recording following established research protocols, with detailed specifications outlined in Attachment A – Statement of Work and additional submission criteria in Attachment D dated July 15, 2026. The solicitation is open to all responsible sources without set-aside restrictions, and offerors must declare their size status under NAICS code 541714 with a 1,000-employee size standard. Evaluation of proposals will prioritize technical acceptability, followed by past performance, and then price, as specified in FAR 52.212-2. Offers must comply with applicable clauses including FAR 52.212-1, 52.212-2, and 52.212-4, as well as NASA-specific clauses such as the Ombudsman provision. All submissions must be delivered electronically to Tracy.L.Quintanilla@nasa.gov and Katelyn.R.Jaime@nasa.gov no later than August 24, 2026, at 1:00 p.m. Central Time. Questions must be submitted via email by July 29, 2026, same time, with no telephone inquiries accepted. Prospective offerors are encouraged to notify the point of contact of their intent to respond, and it is the offeror’s responsibility to download all documents from SAM.gov and ensure timely submission, as late or incomplete offers will be rejected in accordance with FAR provisions.

NASA Johnson Space Center

POSTED

9 days ago

DEADLINE

in about 1 month

View Details

More opportunities from National Aeronautics And Space Administration → NASA Johnson Space Center

Same awarding agency

NAICS: 423450

Federal

Medical and Safety Monitoring Equipment Supply

Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers

POSTED

DEADLINE

Specialized Food and Nutritional Supply for Hypoxia Studies

All Other Miscellaneous Food Manufacturing

POSTED

DEADLINE

Subject Recruitment, Training, and Cognitive Testing Coordination

Offices of All Other Miscellaneous Health Practitioners

POSTED

DEADLINE

Research Protocol and Data Management Services

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Hypoxia Chamber Operations and Technical Support

Testing Laboratories and Services

POSTED

DEADLINE

Hypobaric Chamber Operations and DCS Risk Assessment

Testing Laboratories and Services

POSTED

DEADLINE

VO₂pk Testing and Physiological Monitoring

POSTED

DEADLINE

Human Subject Recruitment and Medical Screening

Offices of All Other Miscellaneous Health Practitioners

POSTED

DEADLINE

Astromaterials Glovebox Systems - Design & Fabrication (A-BOX)This notice from NASA Johnson Space Center, issued as Amendment 1 to Notice 80JSC026A-BOX, is a Request for Information (RFI) for the Design and Fabrication of controlled-atmosphere glovebox systems (A-BOX) to support astromaterials curation at the ARES facility. It is not a solicitation for proposals and no bids are being accepted; its purpose is to gather industry input on technical feasibility, small business participation, organizational conflicts of interest, and overall capability to inform a future acquisition strategy. The requirement encompasses the design, fabrication, testing, delivery, and installation of single-unit, multi-unit, or modular glovebox systems adhering to the American Glovebox Society Guidelines AGS-G001-2007 3rd Edition, with applications tied to NASA’s Artemis program and future lunar and planetary sample returns. Respondents are required to complete and submit the Capability Questions and Responses document, provide feedback on small business subcontracting goals and potential barriers, and address potential organizational conflicts of interest under FAR Subpart 9.5. Access to the A-BOX Technical Library, which includes detailed technical requirements, is restricted and requires completion of a two-step verification process on SAM.gov and submission of the A-BOX Technical Library Request Form to Victoria Miller and Ealena Telson at NASA. All submissions must be sent by the July 29, 2026 deadline and must reference the RFI number in the subject line. Vendors must ensure compliance with U.S. export regulations and verify the accuracy of all information provided. NASA will use all submitted information to shape the forthcoming solicitation and may publish a list of respondents to facilitate teaming, unless a firm explicitly requests to remain anonymous. Responses marked as Confidential Commercial or Financial Information will be protected under the Freedom of Information Act, but the government assumes no obligation to pay for or respond to submissions. Any upcoming solicitation will be posted on SAM.gov, and interested parties must monitor the site independently for updates.

Analytical Laboratory Instrument Manufacturing

POSTED

DEADLINE

Emergency Medical Support and Evacuation (MedEvac) ServicesNASA Johnson Space Center is seeking capabilities submissions for Emergency Medical Support and Evacuation Services to support its global workforce, with the intent to award a follow-on firm fixed price purchase order from October 1, 2026, through September 30, 2031. The services required include comprehensive air and surface medical transport with certified personnel, equipment, and licensed operations to stabilize and evacuate injured or ill travelers to NASA’s designated hospital, whether in the United States or abroad. Additional services encompass bedside case management, medical translation, guaranteed hospital admission and discharge, payment guarantees, repatriation of remains, and specialized support for Soyuz crew landings. The procurement is classified under NAICS code 621910 with a small business size standard of $22.5 million in annual revenue, and all respondents must declare their business size status per FAR Subpart 19.3. Responses must be submitted electronically by July 29, 2026, at 4:00 pm CDT to Kendrea Vallien, and will be evaluated solely to determine if the acquisition will be set aside for small business competition. Oral communications are prohibited, and the Ombudsman clause applies. The solicitation number for the upcoming request for quotes is 80JSC026MEDEVAC5Q.

POSTED

DEADLINE